Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma

被引：36

作者：

Cantarella, Giuseppina ^{[2
]}

Liniger, Matthias ^{[1
]}

Zuniga, Armando ^{[1
]}

Schiller, John T. ^{[3
]}

Billeter, Martin ^{[4
]}

Naim, Hussein Y. ^{[1
]}

Glueck, Reinhard ^{[1
,2
]}

机构：

[1] Crucell Berna Biotech, CH-3018 Bern, Switzerland

[2] Etna Biotech Srl, Catania, Italy

[3] NCI, Cellular Oncol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

[4] Univ Zurich, Inst Mol Biol, Zurich, Switzerland

来源：

VACCINE | 2009年 / 27卷 / 25-26期

关键词：

Recombinant MV; Reverse genetics; HPV-L1; IMMUNE-RESPONSES; PROTEIN; RECEPTOR;

D O I：

10.1016/j.vaccine.2009.01.061

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

071005 [微生物学]; 100108 [医学免疫学];

摘要：

Cervical cancer is mainly associated with HPV genotype 16 infection. Recombinant measles virus (rMV) expressing HPV genotype 16 L1 capsid protein was generated by Construction of an antigenomic plasmid, followed by rescue using the human "helper" cell line 293-3-46. In cell cultures the recombinant MV-L1 virus replicated practically as efficiently as the standard attenuated MV established as commercial vaccine, devoid of the transgene. The high genetic stability of MVb2-L1 was confirmed by 10 serial viral transfers in cell Culture. In transgenic mice expressing the MV receptor CD46 the recombinant induced strong humoral immune responses against both MV and HPV the antibodies against L1 exhibited mainly neutralizing capacity. Our data Suggest that MV is a promising vehicle for development of inexpensive and efficient vaccines protecting from HPV infection. (c) 2009 Elsevier Ltd. All rights reserved.

引用

页码：3385 / 3390

页数：6

共 24 条

[1]

BILLETER MA, CURR TOP MI IN PRESS, pCH7

[2]

Prospects and prejudices of human papillomavirus vaccines in India [J].